Dr. Jonathan Knowles, Chairman – (Executive)
Dr Knowles has been a Non-Executive Director of Adaptimmune since 2010 and became Executive Chairman in November 2013. He was formerly President of Group Research and a Member of the Executive Committee at F.Hoffman-LaRoche Limited, Basel, Switzerland for 12 years. Dr Knowles also served as a Board member at Genentech Inc. for over ten years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, he was Research Director, Glaxo Wellcome Europe.
Dr Knowles has also served as Chairman of the Hever Group and the EFPIA Research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a 2 Billion Euro Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge.
Nicholas Cross, Deputy-Chairman – (Non-Executive)
Nick Cross is a serial entrepreneur and hands on investor. His previous entrepreneurial ventures have included Lansdown Estates Group Ltd. (now MEPC Milton Park Ltd.), Oxford Asymmetry Ltd (now part of Evotec), Oxford Semiconductor Ltd. (now part of PLX Technology, Oxxon (now part of Oxford Biomedica) and Oxagen Ltd. He was a significant investor in and non-executive director of Avidex from 2000 – 2006.
James Noble, Chief Executive Officer
James has been involved with Adaptimmune’s adoptive T cell therapy technology since 1999, when Avidex Limited (the predecessor company to Adaptimmune) was founded. He has over two decades of experience in biotechnology and has served on public and private boards of companies in the UK, the USA and Germany. He is currently Deputy Chairman at GW Pharmaceuticals plc, an AIM-listed biotech company, and is also a non-executive director on the Board of Immunocore, Adaptimmune’s sister company, focused on soluble T cell receptor technology.
Dr. Bent Jakobsen, Chief Scientific Officer
Dr Jakobsen founded Avidex in March 1999 and joined Avidex as full-time Chief Scientific Officer and Executive Board member in July 2000. Bent founded Avidex whilst he was at the Institute of Molecular Medicine (IMM) in Oxford, where he was head of the Immune Receptor Group from 1993 to July 2000. This group is recognised as one of the leading international laboratories in molecular immunology and is a world leader in recombinant immune receptor technology. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark. This followed three years as a Post-doctoral researcher at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.
Dr. Helen Tayton-Martin, Chief Operating Officer
Helen Tayton-Martin is full-time COO of Adaptimmune Ltd. With a PhD in molecular immunology, an MBA from London Business School, she has nearly 20 years of experience working within the Pharma, biotech and consulting environment in disciplines across preclinical and clinical development, strategic planning, due diligence and business development. Helen joined Adaptimmune from Avidex/MediGene Ltd. where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy. Helen is a Director of Adaptimmune Limited and is responsible for all aspects of running the company.